Establishment of Patient-derived Xenografts in Mice.
Establishment of Patient-derived Xenografts in Mice.
复制标题
DOI：
10.21769/bioprotoc.2008
复制
发表时间：
2016-11
期刊：
影响因子：
0.8
通讯作者：
Dongkyoo Park;Dongsheng Wang;Guo Chen;Xingming Deng
中科院分区：
文献类型：
--
作者：
Dongkyoo Park;Dongsheng Wang;Guo Chen;Xingming Deng
用于癌症研究的患者来源的异种移植（PDX）模型最近在学术界和工业界都引起了相当大的关注（Hidalgo等人，2014；Wilding和Bodmer， 2014）。PDX模型已经从包括肺癌在内的不同肿瘤类型中开发出来，以改进药物开发过程。这些模型用于临床前药物评估，并可用于临床结果的预测结果，因为它们保留了肿瘤的原始特征，如异质性、复杂性和分子多样性（Kopetz et al., 2012）。此外，PDX模型为个性化药物治疗提供了潜在的工具。在这个方案中，我们提出了利用小细胞肺癌（SCLC）患者的原发肿瘤组织在小鼠中建立PDX的方法。
Patient-derived xenograft (PDX) models for cancer research have recently attracted considerable attention in both the academy and industry (Hidalgo et al., 2014; Wilding and Bodmer, 2014). PDX models have been developed from different tumor types including lung cancer to improve the drug development process. These models are used for pre-clinical drug evaluation and can be used for the predictive results of clinical outcomes because they conserve original tumor characteristics such as heterogeneity, complexity and molecular diversity (Kopetz et al., 2012). Additionally, PDX model provides the potential tool for the personalized drug therapy. In this protocol, we present methods for the establishment of PDX in mice using primary tumor tissues from patients with small cell lung cancer (SCLC).